Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 523

1.

Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements.

Kallergi G, Aggouraki D, Zacharopoulou N, Stournaras C, Georgoulias V, Martin SS.

Breast Cancer Res. 2018 Jul 5;20(1):67. doi: 10.1186/s13058-018-0993-z.

2.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.

Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC.

JAMA Oncol. 2018 Jun 14. doi: 10.1001/jamaoncol.2018.0775. [Epub ahead of print]

PMID:
29902295
3.

Small cell carcinoma of the stomach: A report of two cases and a review of the literature.

Bakogeorgos M, Kalkanis D, Katsaounis P, Ramfidis V, Speliades C, Pierrakou E, Papadopoulos S, Pantazopoulos N, Georgoulias V, Kotsakis A, Kentepozidis N.

Mol Clin Oncol. 2018 Jul;9(1):11-16. doi: 10.3892/mco.2018.1624. Epub 2018 May 10.

4.

Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study.

Syrigos KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, Charpidou A, Christodoulou C.

Anticancer Res. 2018 Jun;38(6):3735-3744. doi: 10.21873/anticanres.12654.

PMID:
29848736
5.

MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer.

Koutsioumpa M, Chen HW, O'Brien N, Koinis F, Mahurkar-Joshi S, Vorvis C, Soroosh A, Luo T, Issakhanian S, Pantuck AJ, Georgoulias V, Iliopoulos D, Slamon DJ, Drakaki A.

Mol Cancer Ther. 2018 Jul;17(7):1430-1440. doi: 10.1158/1535-7163.MCT-17-1049. Epub 2018 Apr 27.

PMID:
29703843
6.

Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer.

Tryfonidis K, Papadaki C, Assele S, Lagoudaki E, Menis J, Koutsopoulos A, Trypaki M, Tsakalaki E, Sfakianaki M, Hasan B, Stathopoulos E, Georgoulias V, Souglakos J.

Pharmacogenomics J. 2018 Feb 22. doi: 10.1038/s41397-018-0013-9. [Epub ahead of print]

PMID:
29472587
7.

Estrogen receptor-alpha isoforms are the main estrogen receptors expressed in non-small cell lung carcinoma.

Pelekanou V, Anastasiou E, Bakogeorgou E, Notas G, Kampa M, Garcia-Milian R, Lavredaki K, Moustou E, Chinari G, Arapantoni P, O'Grady A, Georgoulias V, Tsapis A, Stathopoulos EN, Castanas E.

Steroids. 2018 Feb 15. pii: S0039-128X(18)30016-3. doi: 10.1016/j.steroids.2018.01.008. [Epub ahead of print]

PMID:
29454903
8.

Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib.

Messaritakis I, Politaki E, Koinis F, Stoltidis D, Apostolaki S, Plataki M, Dermitzaki EK, Georgoulias V, Kotsakis A.

Sci Rep. 2018 Feb 2;8(1):2238. doi: 10.1038/s41598-018-20502-1.

9.

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer.

Kallergi G, Vetsika EK, Aggouraki D, Lagoudaki E, Koutsopoulos A, Koinis F, Katsarlinos P, Trypaki M, Messaritakis I, Stournaras C, Georgoulias V, Kotsakis A.

Ther Adv Med Oncol. 2018 Jan 15;10:1758834017750121. doi: 10.1177/1758834017750121. eCollection 2018.

10.

Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.

Fostira F, Saloustros E, Apostolou P, Vagena A, Kalfakakou D, Mauri D, Tryfonopoulos D, Georgoulias V, Yannoukakos D, Fountzilas G, Konstantopoulou I.

Breast Cancer Res Treat. 2018 May;169(1):105-113. doi: 10.1007/s10549-018-4661-x. Epub 2018 Jan 15.

PMID:
29335925
11.

Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group.

Katsaounis P, Kotsakis A, Kentepozidis N, Polyzos A, Bakogeorgos M, Koinis F, Vamvakas L, Vardakis N, Kalbakis K, Boukovinas I, Varthalitis II, Prinarakis E, Georgoulias V, Souglakos J.

Ann Gastroenterol. 2018 Jan-Feb;31(1):65-70. doi: 10.20524/aog.2017.0215. Epub 2017 Nov 27.

12.

Association of epithelial-to-mesenchymal transition circulating tumor cells in non-small cell lung cancer (NSCLC) molecular subgroups.

Messaritakis I, Kotsakis A, Georgoulias V.

J Thorac Dis. 2017 Dec;9(12):4817-4820. doi: 10.21037/jtd.2017.11.106. No abstract available.

13.

ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment.

Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Politaki E, Voutsina A, Psyrri A, Georgoulias V, Lianidou E.

Clin Cancer Res. 2018 Mar 15;24(6):1500-1510. doi: 10.1158/1078-0432.CCR-17-1181. Epub 2017 Dec 28.

PMID:
29284708
14.

2nd Symposium on Advances in Cancer Immunology and Immunotherapy, December 15-17, 2016, Athens, Greece.

Samara P, Kotsakis A, Tsitsilonis O, Georgoulias V, Pawelec G, Baxevanis CN.

Cancer Immunol Immunother. 2018 Jan;67(1):153-159. doi: 10.1007/s00262-017-2096-6. Epub 2017 Dec 1.

PMID:
29196790
15.

A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer.

Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F, Perraki M, Saloustrou G, Stoupis G, Kallergi G, Spiliotaki M, Skaltsi T, Lianidou E, Georgoulias V, Mavroudis D.

Cell Physiol Biochem. 2017;44(2):594-606. doi: 10.1159/000485115. Epub 2017 Nov 20.

16.

Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.

Saloustros E, Nikolaou M, Kalbakis K, Polyzos A, Christofillakis C, Kentepozidis N, Pistamaltzian N, Kourousis C, Vamvakas L, Georgoulias V, Mavroudis D.

Clin Breast Cancer. 2018 Feb;18(1):88-94. doi: 10.1016/j.clbc.2017.10.013. Epub 2017 Oct 24.

PMID:
29153775
17.

Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer.

Chimonidou M, Strati A, Malamos N, Kouneli S, Georgoulias V, Lianidou E.

Oncotarget. 2017 Jun 27;8(42):72054-72068. doi: 10.18632/oncotarget.18679. eCollection 2017 Sep 22.

18.

Association analysis identifies 65 new breast cancer risk loci.

Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A, Soucy P, Glubb D, Rostamianfar A, Bolla MK, Wang Q, Tyrer J, Dicks E, Lee A, Wang Z, Allen J, Keeman R, Eilber U, French JD, Qing Chen X, Fachal L, McCue K, McCart Reed AE, Ghoussaini M, Carroll JS, Jiang X, Finucane H, Adams M, Adank MA, Ahsan H, Aittomäki K, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Arun B, Auer PL, Bacot F, Barrdahl M, Baynes C, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brand JS, Brauch H, Brennan P, Brenner H, Brinton L, Broberg P, Brock IW, Broeks A, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Butterbach K, Cai Q, Cai H, Caldés T, Canzian F, Carracedo A, Carter BD, Castelao JE, Chan TL, David Cheng TY, Seng Chia K, Choi JY, Christiansen H, Clarke CL; NBCS Collaborators, Collée M, Conroy DM, Cordina-Duverger E, Cornelissen S, Cox DG, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Devilee P, Doheny KF, Dörk T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Elvira M, Engel C, Eriksson M, Fasching PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fritschi L, Gaborieau V, Gabrielson M, Gago-Dominguez M, Gao YT, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulias V, Giles GG, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J, Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hamel N, Hankinson S, Harrington P, Hart SN, Hartikainen JM, Hartman M, Hein A, Heyworth J, Hicks B, Hillemanns P, Ho DN, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Hou MF, Hsiung CN, Huang G, Humphreys K, Ishiguro J, Ito H, Iwasaki M, Iwata H, Jakubowska A, Janni W, John EM, Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kaczmarek K, Kang D, Kasuga Y, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kim SW, Knight JA, Kosma VM, Kristensen VN, Krüger U, Kwong A, Lambrechts D, Le Marchand L, Lee E, Lee MH, Lee JW, Neng Lee C, Lejbkowicz F, Li J, Lilyquist J, Lindblom A, Lissowska J, Lo WY, Loibl S, Long J, Lophatananon A, Lubinski J, Luccarini C, Lux MP, Ma ESK, MacInnis RJ, Maishman T, Makalic E, Malone KE, Kostovska IM, Mannermaa A, Manoukian S, Manson JE, Margolin S, Mariapun S, Martinez ME, Matsuo K, Mavroudis D, McKay J, McLean C, Meijers-Heijboer H, Meindl A, Menéndez P, Menon U, Meyer J, Miao H, Miller N, Taib NAM, Muir K, Mulligan AM, Mulot C, Neuhausen SL, Nevanlinna H, Neven P, Nielsen SF, Noh DY, Nordestgaard BG, Norman A, Olopade OI, Olson JE, Olsson H, Olswold C, Orr N, Pankratz VS, Park SK, Park-Simon TW, Lloyd R, Perez JIA, Peterlongo P, Peto J, Phillips KA, Pinchev M, Plaseska-Karanfilska D, Prentice R, Presneau N, Prokofyeva D, Pugh E, Pylkäs K, Rack B, Radice P, Rahman N, Rennert G, Rennert HS, Rhenius V, Romero A, Romm J, Ruddy KJ, Rüdiger T, Rudolph A, Ruebner M, Rutgers EJT, Saloustros E, Sandler DP, Sangrajrang S, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schürmann P, Scott RJ, Scott C, Seal S, Seynaeve C, Shah M, Sharma P, Shen CY, Sheng G, Sherman ME, Shrubsole MJ, Shu XO, Smeets A, Sohn C, Southey MC, Spinelli JJ, Stegmaier C, Stewart-Brown S, Stone J, Stram DO, Surowy H, Swerdlow A, Tamimi R, Taylor JA, Tengström M, Teo SH, Beth Terry M, Tessier DC, Thanasitthichai S, Thöne K, Tollenaar RAEM, Tomlinson I, Tong L, Torres D, Truong T, Tseng CC, Tsugane S, Ulmer HU, Ursin G, Untch M, Vachon C, van Asperen CJ, Van Den Berg D, van den Ouweland AMW, van der Kolk L, van der Luijt RB, Vincent D, Vollenweider J, Waisfisz Q, Wang-Gohrke S, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Wu AH, Xia L, Yamaji T, Yang XR, Har Yip C, Yoo KY, Yu JC, Zheng W, Zheng Y, Zhu B, Ziogas A, Ziv E; ABCTB Investigators; ConFab/AOCS Investigators, Lakhani SR, Antoniou AC, Droit A, Andrulis IL, Amos CI, Couch FJ, Pharoah PDP, Chang-Claude J, Hall P, Hunter DJ, Milne RL, García-Closas M, Schmidt MK, Chanock SJ, Dunning AM, Edwards SL, Bader GD, Chenevix-Trench G, Simard J, Kraft P, Easton DF.

Nature. 2017 Nov 2;551(7678):92-94. doi: 10.1038/nature24284. Epub 2017 Oct 23.

19.

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.

Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J, Jiang X, Rostamianfar A, Finucane H, Bolla MK, McGuffog L, Wang Q, Aalfs CM; ABCTB Investigators, Adams M, Adlard J, Agata S, Ahmed S, Ahsan H, Aittomäki K, Al-Ejeh F, Allen J, Ambrosone CB, Amos CI, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Auber B, Auer PL, Ausems MGEM, Azzollini J, Bacot F, Balmaña J, Barile M, Barjhoux L, Barkardottir RB, Barrdahl M, Barnes D, Barrowdale D, Baynes C, Beckmann MW, Benitez J, Bermisheva M, Bernstein L, Bignon YJ, Blazer KR, Blok MJ, Blomqvist C, Blot W, Bobolis K, Boeckx B, Bogdanova NV, Bojesen A, Bojesen SE, Bonanni B, Børresen-Dale AL, Bozsik A, Bradbury AR, Brand JS, Brauch H, Brenner H, Bressac-de Paillerets B, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Brunet J, Brüning T, Burwinkel B, Buys SS, Byun J, Cai Q, Caldés T, Caligo MA, Campbell I, Canzian F, Caron O, Carracedo A, Carter BD, Castelao JE, Castera L, Caux-Moncoutier V, Chan SB, Chang-Claude J, Chanock SJ, Chen X, Cheng TD, Chiquette J, Christiansen H, Claes KBM, Clarke CL, Conner T, Conroy DM, Cook J, Cordina-Duverger E, Cornelissen S, Coupier I, Cox A, Cox DG, Cross SS, Cuk K, Cunningham JM, Czene K, Daly MB, Damiola F, Darabi H, Davidson R, De Leeneer K, Devilee P, Dicks E, Diez O, Ding YC, Ditsch N, Doheny KF, Domchek SM, Dorfling CM, Dörk T, Dos-Santos-Silva I, Dubois S, Dugué PA, Dumont M, Dunning AM, Durcan L, Dwek M, Dworniczak B, Eccles D, Eeles R, Ehrencrona H, Eilber U, Ejlertsen B, Ekici AB, Eliassen AH; EMBRACE, Engel C, Eriksson M, Fachal L, Faivre L, Fasching PA, Faust U, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Foulkes WD, Friedman E, Fritschi L, Frost D, Gabrielson M, Gaddam P, Gammon MD, Ganz PA, Gapstur SM, Garber J, Garcia-Barberan V, García-Sáenz JA, Gaudet MM, Gauthier-Villars M, Gehrig A; GEMO Study Collaborators, Georgoulias V, Gerdes AM, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Goodfellow P, Greene MH, Alnæs GIG, Grip M, Gronwald J, Grundy A, Gschwantler-Kaulich D, Guénel P, Guo Q, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hallberg E, Hamann U, Hamel N, Hankinson S, Hansen TVO, Harrington P, Hart SN, Hartikainen JM, Healey CS; HEBON, Hein A, Helbig S, Henderson A, Heyworth J, Hicks B, Hillemanns P, Hodgson S, Hogervorst FB, Hollestelle A, Hooning MJ, Hoover B, Hopper JL, Hu C, Huang G, Hulick PJ, Humphreys K, Hunter DJ, Imyanitov EN, Isaacs C, Iwasaki M, Izatt L, Jakubowska A, James P, Janavicius R, Janni W, Jensen UB, John EM, Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kaczmarek K, Kang D, Kast K; kConFab/AOCS Investigators, Keeman R, Kerin MJ, Kets CM, Keupers M, Khan S, Khusnutdinova E, Kiiski JI, Kim SW, Knight JA, Konstantopoulou I, Kosma VM, Kristensen VN, Kruse TA, Kwong A, Lænkholm AV, Laitman Y, Lalloo F, Lambrechts D, Landsman K, Lasset C, Lazaro C, Le Marchand L, Lecarpentier J, Lee A, Lee E, Lee JW, Lee MH, Lejbkowicz F, Lesueur F, Li J, Lilyquist J, Lincoln A, Lindblom A, Lissowska J, Lo WY, Loibl S, Long J, Loud JT, Lubinski J, Luccarini C, Lush M, MacInnis RJ, Maishman T, Makalic E, Kostovska IM, Malone KE, Manoukian S, Manson JE, Margolin S, Martens JWM, Martinez ME, Matsuo K, Mavroudis D, Mazoyer S, McLean C, Meijers-Heijboer H, Menéndez P, Meyer J, Miao H, Miller A, Miller N, Mitchell G, Montagna M, Muir K, Mulligan AM, Mulot C, Nadesan S, Nathanson KL; NBSC Collaborators, Neuhausen SL, Nevanlinna H, Nevelsteen I, Niederacher D, Nielsen SF, Nordestgaard BG, Norman A, Nussbaum RL, Olah E, Olopade OI, Olson JE, Olswold C, Ong KR, Oosterwijk JC, Orr N, Osorio A, Pankratz VS, Papi L, Park-Simon TW, Paulsson-Karlsson Y, Lloyd R, Pedersen IS, Peissel B, Peixoto A, Perez JIA, Peterlongo P, Peto J, Pfeiler G, Phelan CM, Pinchev M, Plaseska-Karanfilska D, Poppe B, Porteous ME, Prentice R, Presneau N, Prokofieva D, Pugh E, Pujana MA, Pylkäs K, Rack B, Radice P, Rahman N, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rennert HS, Rhenius V, Rhiem K, Richardson A, Rodriguez GC, Romero A, Romm J, Rookus MA, Rudolph A, Ruediger T, Saloustros E, Sanders J, Sandler DP, Sangrajrang S, Sawyer EJ, Schmidt DF, Schoemaker MJ, Schumacher F, Schürmann P, Schwentner L, Scott C, Scott RJ, Seal S, Senter L, Seynaeve C, Shah M, Sharma P, Shen CY, Sheng X, Shimelis H, Shrubsole MJ, Shu XO, Side LE, Singer CF, Sohn C, Southey MC, Spinelli JJ, Spurdle AB, Stegmaier C, Stoppa-Lyonnet D, Sukiennicki G, Surowy H, Sutter C, Swerdlow A, Szabo CI, Tamimi RM, Tan YY, Taylor JA, Tejada MI, Tengström M, Teo SH, Terry MB, Tessier DC, Teulé A, Thöne K, Thull DL, Tibiletti MG, Tihomirova L, Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Tong L, Torres D, Tranchant M, Truong T, Tucker K, Tung N, Tyrer J, Ulmer HU, Vachon C, van Asperen CJ, Van Den Berg D, van den Ouweland AMW, van Rensburg EJ, Varesco L, Varon-Mateeva R, Vega A, Viel A, Vijai J, Vincent D, Vollenweider J, Walker L, Wang Z, Wang-Gohrke S, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wesseling J, Whittemore AS, Wijnen JT, Willett W, Winqvist R, Wolk A, Wu AH, Xia L, Yang XR, Yannoukakos D, Zaffaroni D, Zheng W, Zhu B, Ziogas A, Ziv E, Zorn KK, Gago-Dominguez M, Mannermaa A, Olsson H, Teixeira MR, Stone J, Offit K, Ottini L, Park SK, Thomassen M, Hall P, Meindl A, Schmutzler RK, Droit A, Bader GD, Pharoah PDP, Couch FJ, Easton DF, Kraft P, Chenevix-Trench G, García-Closas M, Schmidt MK, Antoniou AC, Simard J.

Nat Genet. 2017 Dec;49(12):1767-1778. doi: 10.1038/ng.3785. Epub 2017 Oct 23.

20.

Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy.

Bakogeorgos M, Georgoulias V.

Expert Rev Anticancer Ther. 2017 Nov;17(11):1045-1060. doi: 10.1080/14737140.2017.1374856. Epub 2017 Sep 11. Review.

PMID:
28868935
21.

Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes.

Spiliotaki M, Mavroudis D, Kokotsaki M, Vetsika EK, Stoupis I, Matikas A, Kallergi G, Georgoulias V, Agelaki S.

Mol Oncol. 2018 Jan;12(1):21-32. doi: 10.1002/1878-0261.12114. Epub 2017 Nov 16.

22.

Lung cancer and annual mean exposure to outdoor air pollution in Crete, Greece.

Sifaki-Pistolla D, Lionis C, Koinis F, Georgoulias V, Tzanakis N; Cancer Registry of Crete (CRC).

Eur J Cancer Prev. 2017 Sep;26 Joining forces for better cancer registration in Europe:S208-S214. doi: 10.1097/CEJ.0000000000000407.

PMID:
28746162
23.

Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer.

Messaritakis I, Politaki E, Kotsakis A, Dermitzaki EK, Koinis F, Lagoudaki E, Koutsopoulos A, Kallergi G, Souglakos J, Georgoulias V.

PLoS One. 2017 Jul 18;12(7):e0181211. doi: 10.1371/journal.pone.0181211. eCollection 2017.

24.

Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer.

Matikas A, Voutsina A, Lagoudaki E, Hatzidaki D, Trypaki M, Stoupis G, Tzardi M, Mavroudis D, Georgoulias V.

Transl Oncol. 2017 Aug;10(4):693-698. doi: 10.1016/j.tranon.2017.06.005. Epub 2017 Jul 7.

25.

Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.

Mavroudis D, Saloustros E, Boukovinas I, Papakotoulas P, Kakolyris S, Ziras N, Christophylakis C, Kentepozidis N, Fountzilas G, Rigas G, Varthalitis I, Kalbakis K, Agelaki S, Hatzidaki D, Georgoulias V.

Br J Cancer. 2017 Jul 11;117(2):164-170. doi: 10.1038/bjc.2017.158. Epub 2017 Jun 22.

26.

Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.

Koinis F, Voutsina A, Kalikaki A, Koutsopoulos A, Lagoudaki E, Tsakalaki E, Dermitzaki EK, Kontopodis E, Pallis AG, Georgoulias V, Kotsakis A.

Clin Transl Oncol. 2018 Feb;20(2):140-149. doi: 10.1007/s12094-017-1702-6. Epub 2017 Jun 19.

PMID:
28631135
27.

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.

Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, Lu S, Cobo M, Syrigos K, Lee KH, Göker E, Guclu SZ, Isla D, Morabito A, Dupuis N, Bühnemann C, Krämer N, Solca F, Ehrnrooth E, Ardizzoni A.

Lung Cancer. 2017 Jul;109:101-108. doi: 10.1016/j.lungcan.2017.05.010. Epub 2017 May 11.

28.

Application of data mining techniques and data analysis methods to measure cancer morbidity and mortality data in a regional cancer registry: The case of the island of Crete, Greece.

Varlamis I, Apostolakis I, Sifaki-Pistolla D, Dey N, Georgoulias V, Lionis C.

Comput Methods Programs Biomed. 2017 Jul;145:73-83. doi: 10.1016/j.cmpb.2017.04.011. Epub 2017 Apr 13.

PMID:
28552128
29.

Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.

Milaki G, Messaritakis I, Koinis F, Kotsakis A, Apostolaki S, Dermitzaki EK, Perraki M, Hatzidaki D, Georgoulias V.

Cancer Chemother Pharmacol. 2017 Jul;80(1):101-108. doi: 10.1007/s00280-017-3339-0. Epub 2017 May 18.

PMID:
28523597
30.

Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.

Koinis F, Agelaki S, Karavassilis V, Kentepozidis N, Samantas E, Peroukidis S, Katsaounis P, Hartabilas E, Varthalitis II, Messaritakis I, Fountzilas G, Georgoulias V, Kotsakis A.

Br J Cancer. 2017 Jun 27;117(1):8-14. doi: 10.1038/bjc.2017.137. Epub 2017 May 16.

31.

Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types.

Kotsakis A, Georgoulias V.

Lancet Oncol. 2017 May;18(5):556-557. doi: 10.1016/S1470-2045(17)30227-9. Epub 2017 Mar 31. No abstract available.

PMID:
28373006
32.

TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC).

Messaritakis I, Stoltidis D, Kotsakis A, Dermitzaki EK, Koinis F, Lagoudaki E, Koutsopoulos A, Politaki E, Apostolaki S, Souglakos J, Georgoulias V.

Sci Rep. 2017 Mar 28;7:45351. doi: 10.1038/srep45351.

33.

Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients.

Papadakis GZ, Mavroudis D, Georgoulias V, Souglakos J, Alegakis AK, Samonis G, Bagci U, Makrigiannakis A, Zoras O.

Growth Horm IGF Res. 2017 Apr;33:28-34. doi: 10.1016/j.ghir.2017.02.001. Epub 2017 Feb 16.

PMID:
28258988
34.

Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.

Messaritakis I, Politaki E, Plataki M, Karavassilis V, Kentepozidis N, Koinis F, Samantas E, Georgoulias V, Kotsakis A.

Lung Cancer. 2017 Feb;104:16-23. doi: 10.1016/j.lungcan.2016.12.008. Epub 2016 Dec 14.

PMID:
28212995
35.

Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer.

Matikas A, Foukakis T, Michalakis I, Georgoulias V.

Expert Rev Anticancer Ther. 2017 Apr;17(4):319-326. doi: 10.1080/14737140.2017.1288105. Epub 2017 Feb 9. Review.

PMID:
28128984
36.

Lung cancer and tobacco smoking in Crete, Greece: reflections from a population-based cancer registry from 1992 to 2013.

Sifaki-Pistolla D, Lionis C, Georgoulias V, Kyriakidis P, Koinis F, Aggelaki S, Tzanakis N.

Tob Induc Dis. 2017 Jan 19;15:6. doi: 10.1186/s12971-017-0114-2. eCollection 2017.

37.

Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity.

Matikas A, Mistriotis D, Georgoulias V, Kotsakis A.

Crit Rev Oncol Hematol. 2017 Feb;110:1-12. doi: 10.1016/j.critrevonc.2016.12.005. Epub 2016 Dec 9. Review.

PMID:
28109399
38.

Role of circulating free DNA in colorectal cancer.

Matikas A, Voutsina A, Trypaki M, Georgoulias V.

World J Gastrointest Oncol. 2016 Dec 15;8(12):810-818. doi: 10.4251/wjgo.v8.i12.810. Review.

39.

Classifying circulating tumor cells to monitor cancer progression.

Economopoulou P, Georgoulias V, Kotsakis A.

Expert Rev Mol Diagn. 2017 Feb;17(2):153-165. doi: 10.1080/14737159.2017.1275572. Epub 2016 Dec 29. Review.

PMID:
28032524
40.

Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.

Agelaki S, Dragolia M, Markonanolaki H, Alkahtani S, Stournaras C, Georgoulias V, Kallergi G.

Oncotarget. 2017 Jan 17;8(3):5309-5322. doi: 10.18632/oncotarget.14144.

41.

Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients.

Kotsakis A, Koinis F, Katsarou A, Gioulbasani M, Aggouraki D, Kentepozidis N, Georgoulias V, Vetsika EK.

Sci Rep. 2016 Dec 15;6:39247. doi: 10.1038/srep39247.

42.

Evaluation of Isolation Methods for Circulating Tumor Cells (CTCs).

Kallergi G, Politaki E, Alkahtani S, Stournaras C, Georgoulias V.

Cell Physiol Biochem. 2016;40(3-4):411-419. Epub 2016 Nov 25.

43.

Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.

Pontikakis S, Papadaki C, Tzardi M, Trypaki M, Sfakianaki M, Koinis F, Lagoudaki E, Giannikaki L, Kalykaki A, Kontopodis E, Saridaki Z, Malamos N, Georgoulias V, Souglakos J.

Pharmacogenomics J. 2017 Dec;17(6):506-514. doi: 10.1038/tpj.2016.63. Epub 2016 Oct 25.

PMID:
27779244
44.

Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group.

Karampeazis A, Vamvakas L, Kentepozidis N, Polyzos A, Chandrinos V, Rigas G, Christofyllakis C, Kotsakis A, Hatzidaki D, Pallis AG, Georgoulias V.

Clin Lung Cancer. 2016 Nov;17(6):543-549. doi: 10.1016/j.cllc.2016.05.009. Epub 2016 Jun 2.

PMID:
27397849
45.

Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer.

Matikas A, Kentepozidis N, Georgoulias V, Kotsakis A.

Clin Lung Cancer. 2016 Nov;17(6):474-482. doi: 10.1016/j.cllc.2016.05.006. Epub 2016 Jun 2. Review.

PMID:
27341790
46.

Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.

Robles AI, Olsen KS, Tsui DW, Georgoulias V, Creaney J, Dobra K, Vyberg M, Minato N, Anders RA, Børresen-Dale AL, Zhou J, Sætrom P, Nielsen BS, Kirschner MB, Krokan HE, Papadimitrakopoulou V, Tsamardinos I, Røe OD.

J Transl Med. 2016 Oct 19;14(1):295.

47.

Distinction between breast cancer cell subtypes using third harmonic generation microscopy.

Gavgiotaki E, Filippidis G, Markomanolaki H, Kenanakis G, Agelaki S, Georgoulias V, Athanassakis I.

J Biophotonics. 2017 Sep;10(9):1152-1162. doi: 10.1002/jbio.201600173. Epub 2016 Oct 18.

PMID:
27753229
48.

The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update.

Matikas A, Georgoulias V, Kotsakis A.

Expert Rev Respir Med. 2016 Oct 3:1-13. [Epub ahead of print]

PMID:
27661451
49.

Targeting angiogenesis in small cell lung cancer.

Stratigos M, Matikas A, Voutsina A, Mavroudis D, Georgoulias V.

Transl Lung Cancer Res. 2016 Aug;5(4):389-400. doi: 10.21037/tlcr.2016.08.04. Review.

50.

A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.

Kotsakis A, Matikas A, Koinis F, Kentepozidis N, Varthalitis II, Karavassilis V, Samantas E, Katsaounis P, Dermitzaki EK, Hatzidaki D, Mavroudis D, Georgoulias V.

Br J Cancer. 2016 Sep 27;115(7):784-8. doi: 10.1038/bjc.2016.281. Epub 2016 Sep 8.

Supplemental Content

Loading ...
Support Center